betovumeline fesoterodine (ML-007C-MA) — Topline data
H2 2027
Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027Source filing
MPLT biotech catalysts & pipeline
MAPLIGHT THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
betovumeline fesoterodine (ML-007C-MA) — Topline data
2028
The Company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, including the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.Source filing